> Detailanzeige

Koutouzis, Michael; Lagerqvist, Bo; Oldgren, Jonas; Åkerblom, Axel; Wahlin, Magnus; Karlsson, Thomas; Albertsson, Per; Matejka, Göran; Grip, Lars

Long‐Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Long‐Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention
  • Beteiligte: Koutouzis, Michael; Lagerqvist, Bo; Oldgren, Jonas; Åkerblom, Axel; Wahlin, Magnus; Karlsson, Thomas; Albertsson, Per; Matejka, Göran; Grip, Lars
  • Erschienen: Wiley, 2010
  • Erschienen in: Clinical Cardiology
  • Sprache: Englisch
  • DOI: 10.1002/clc.20814
  • ISSN: 1932-8737; 0160-9289
  • Schlagwörter: Cardiology and Cardiovascular Medicine ; General Medicine
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background:</jats:title><jats:p>The usage of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors improves the outcome during high‐risk percutaneous coronary interventions (PCI). The aim of this study was to evaluate the long‐term effects after a planned switch from abciximab to eptifibatide during PCI.</jats:p></jats:sec><jats:sec><jats:title>Hypothesis:</jats:title><jats:p>A switch from the general use of abciximab to eptifibatide as a GP IIb/IIIa in connection with PCI would not have any negative effects on long‐term clinical outcomes.</jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p>To reduce costs, a general switch from abciximab to eptifibatide was instituted in 2004 in 2 university hospitals in Sweden. All patients treated 6 months before and 6 months after the switch were followed for 30 months. During the study period, 1038 patients underwent PCI and received a GP IIb/IIIa receptor inhibitor, 481 (46%) before the switch (Group A) and 557 (54%) after the switch (Group B). The 2 groups had similar baseline characteristics. The primary endpoint was the composite of death, myocardial infarction, stroke, or new coronary revascularization (percutaneous or surgical); secondary endpoints were the individual components of this composite. A separate analysis was performed on patients treated for ST‐segment elevation myocardial infarction, non–ST‐segment elevation myocardial infarction/unstable angina, and diabetes, respectively. Data were collected from the Swedish Coronary Angiography and Angioplasty Registry.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>There were no differences between the groups in the primary endpoint (29.7% in Group A vs 29.3% in Group B; <jats:italic>P</jats:italic> = 0.48) or in any of the secondary endpoints.</jats:p></jats:sec><jats:sec><jats:title>Conclusions:</jats:title><jats:p>A switch from the general usage of abciximab to eptifibatide as a GP IIb/IIIa receptor inhibitor in connection with PCI did not seem to have any negative effects on long‐term clinical outcomes. Copyright © 2008 Wiley Periodicals, Inc.</jats:p><jats:p>The authors have no funding, financial relationships, or conflicts of interest to disclose.</jats:p></jats:sec>
  • Zugangsstatus: Freier Zugang